UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY

At the MURANO trial (NCT02005471) 5-yr update, median (95% CI) progression-free survival (PFS) was 54 (48–57) mo with venetoclax-rituximab (VenR) and 17 (15–22) mo with bendamustine-R (BR); 36% of pts on VenR and 63% on BR had received new anti-CLL therapy. A substudy from 2018 onward enrolled 34 R/R CLL pts with progressive disease (PD) after initial treatment (tx) to receive VenR as re-tx (n=25) or crossover from BR (n=9). We report on pts who...